Elicio Therapeutics Statistics Share Statistics Elicio Therapeutics has 16.34M
shares outstanding. The number of shares has increased by 48.47%
in one year.
Shares Outstanding 16.34M Shares Change (YoY) 48.47% Shares Change (QoQ) 0.85% Owned by Institutions (%) 12.29% Shares Floating 6.81M Failed to Deliver (FTD) Shares 530 FTD / Avg. Volume 0.68%
Short Selling Information The latest short interest is 416.96K, so 2.61% of the outstanding
shares have been sold short.
Short Interest 416.96K Short % of Shares Out 2.61% Short % of Float 4.04% Short Ratio (days to cover) 9.83
Valuation Ratios The PE ratio is -1.2 and the forward
PE ratio is -6.03.
Elicio Therapeutics's PEG ratio is
0.03.
PE Ratio -1.2 Forward PE -6.03 PS Ratio 0 Forward PS 8.7 PB Ratio -5.5 P/FCF Ratio -1.68 PEG Ratio 0.03
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Elicio Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 1.8,
with a Debt / Equity ratio of -2.3.
Current Ratio 1.8 Quick Ratio 1.8 Debt / Equity -2.3 Debt / EBITDA -0.52 Debt / FCF -0.7 Interest Coverage -98.87
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.62M Employee Count 32 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 163.68% in the
last 52 weeks. The beta is 2.15, so Elicio Therapeutics's
price volatility has been higher than the market average.
Beta 2.15 52-Week Price Change 163.68% 50-Day Moving Average 9.24 200-Day Moving Average 7.13 Relative Strength Index (RSI) 55.09 Average Volume (20 Days) 77,414
Income Statement
Revenue n/a Gross Profit -1.18M Operating Income -44.99M Net Income -51.9M EBITDA -50.27M EBIT -51.44M Earnings Per Share (EPS) -4.25
Full Income Statement Balance Sheet The company has 17.62M in cash and 26.04M in
debt, giving a net cash position of -8.42M.
Cash & Cash Equivalents 17.62M Total Debt 26.04M Net Cash -8.42M Retained Earnings -194.1M Total Assets 29.53M Working Capital 12.68M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -37.07M
and capital expenditures -87K, giving a free cash flow of -37.16M.
Operating Cash Flow -37.07M Capital Expenditures -87K Free Cash Flow -37.16M FCF Per Share -3.04
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields ELTX does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for ELTX is $11,
which is 3.8% higher than the current price. The consensus rating is "Strong Buy".
Price Target $11 Price Target Difference 3.8% Analyst Consensus Strong Buy Analyst Count 2
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Jun 2, 2023. It was a
backward
split with a ratio of 1:10.
Last Split Date Jun 2, 2023 Split Type backward Split Ratio 1:10
Scores Altman Z-Score -12.64 Piotroski F-Score 3
